ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
14 mars 2025 16h03 HE
|
NurExone Biologic Inc
ExoPTEN’s Preclinical Study Demonstrates Significant for Enhancing Motor Function, Increasing Blood Flow, and Faster Recovery After Spinal Cord Injuries
Hepion Pharmaceuticals Announces Reverse Stock Split
14 mars 2025 08h30 HE
|
Hepion Pharmaceuticals, Inc.
Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage...
Spineart and eCential Robotics announce FDA clearance of PERLA® App for use with Op.nTM robotic navigation platform
13 mars 2025 05h56 HE
|
Spineart
FOR IMMEDIATE RELEASE Spineart and eCential Robotics announce FDA clearance of PERLA® App for use with Op.nTM robotic navigation platform Dallas, Texas and Franklin, Tennessee, March 13, 2025 —...
Interim analysis of 1-level BAGUERA®C IDE study meets threshold for non-inferiority
11 mars 2025 07h00 HE
|
Spineart
Interim analysis of 1-level BAGUERA®C IDE study meets threshold for non-inferiority Geneva, March 11, 2025 – Spineart, a fast-growing company in spine surgery innovation, today announces that it has...
Interim analysis of 1-level BAGUERA®C IDE study meets threshold for non-inferiority
11 mars 2025 02h00 HE
|
Spineart
Press Release – To post on March 11, 2025 Interim analysis of 1-level BAGUERA®C IDE study meets threshold for non-inferiority Geneva, March 11, 2025 – Spineart, a fast-growing company in spine...
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
10 mars 2025 08h30 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
10 mars 2025 08h30 HE
|
Biodexa Pharmaceuticals PLC
March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S....
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
04 mars 2025 08h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study
03 mars 2025 09h01 HE
|
PharmAla Biotech
PharmAla completes historic first shipment of MDMA from Canada to USA for use in a UCLA Clinical Trial
F.A.S.T.® aiCockpit® CT Lung Nodule Software Receives FDA 510(k) Clearance
03 mars 2025 09h00 HE
|
Fovia, Inc.
Provides Efficient Interaction with Consolidated AI Results PALO ALTO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Fovia Ai, Inc., an innovative leader in AI findings analysis and workflow software,...